Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model
| Autor: | Torsten Malm, L Bagge, E Holmer, H Tydén, S O Nyström, T Wahlberg |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Dalteparin
Male medicine.medical_specialty medicine.drug_class Swine Blood Loss Surgical Low molecular weight heparin law.invention Random Allocation Bolus (medicine) law Cardiopulmonary bypass Medicine Animals Protamines Cardiac Surgical Procedures Monitoring Physiologic Postoperative Care Cardiopulmonary Bypass Intraoperative Care biology medicine.diagnostic_test Dose-Response Relationship Drug business.industry Heparin Anticoagulant Thrombosis Hematology General Medicine Protamine Surgery Disease Models Animal Anesthesia biology.protein Female business Activated Coagulation Time circulatory and respiratory physiology medicine.drug Partial thromboplastin time |
| Zdroj: | Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 5(2) |
| ISSN: | 0957-5235 |
| Popis: | Fragmin and heparin were studied in pigs during 120 min of cardiopulmonary bypass (CPB) and up to 240 min postoperatively, with respect to clotting, bleeding and the effects of protamine. Thirty-three pigs received bolus injections of 300 IU/kg with or without additional dosage during CPB and with or without subsequent protamine sulphate. Doses of Fragmin 60% higher were necessary to prevent clotting. These had 100% higher anti-FXa levels but about 50% shorter activated coagulation time (ACT) compared with heparin. Anti-FXa increased with cumulative doses of heparin and Fragmin but ACT and activated partial thromboplastin time (aPTT) did not, indicating a larger loss of thrombin inhibition compared with anti-FXa in both drugs during CPB. Thrombin inhibition was crucial for prevention of clotting. Protamine efficiently normalized ACT in the Fragmin group but left a residual 20% anti-FXa, which did not increase the bleeding tendency. Fragmin could adequately be monitored with ACT and would be a safe alternative to heparin in CPB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|